Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MENOPUR vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Induction of ovulation in patients with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Off-label: Treatment of male hypogonadotropic hypogonadism (in combination with human chorionic gonadotropin)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Metabolism is not fully characterized; renally excreted as intact protein.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 10-20% bound to plasma proteins, primarily albumin.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Subcutaneous or intramuscular: Approximately 70-80% due to partial local degradation; oral bioavailability is negligible (<1%).
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to limited data, consider risk of fluid retention.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) as metabolism is hepatic; use with caution in Child-Pugh class B.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated; no established pediatric dosing.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for geriatric patients; no dosing recommendations.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
MENOPUR should only be used by physicians who are experienced in infertility diagnosis and management. Use may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and result in pulmonary embolism, stroke, ovarian torsion, or death. Use should be avoided in women with a high baseline FSH level indicating primary ovarian failure.
None.
Ovarian Hyperstimulation Syndrome (OHSS) - risk minimized by monitoring estradiol levels and ultrasound; discontinue if severe.,Multiple pregnancy - high risk; counseling is required.,Ovarian enlargement - usually resolves without treatment.,Pulmonary embolism and arterial thromboembolism - especially in severe OHSS.,Ovarian torsion - consider in patients with severe OHSS.,Ectopic pregnancy - increased risk in patients with tubal disease.,Congenital malformations - incidence similar to natural conception.,Ovarian neoplasms - no definitive causal link, but caution.
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Hypersensitivity to menotropins or any component.,High baseline FSH indicating primary ovarian failure.,Uncontrolled thyroid or adrenal dysfunction.,Organic intracranial lesion (e.g., pituitary tumor).,Abnormal uterine bleeding of undetermined origin.,Ovarian cysts or enlargement of undetermined origin (not due to PCOS).,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine).,Pregnancy and lactation.
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No clinically relevant food interactions have been reported. Patients should maintain a normal balanced diet. Grapefruit and grapefruit juice are not known to interact with menotropins. No restriction on caffeine or dairy products.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects, congenital heart defects, and multiple anomalies, likely related to the underlying infertility and assisted reproductive technology rather than direct teratogenicity. Second and third trimester risks include preterm labor, low birth weight, and perinatal mortality due to multiple gestation and ovarian hyperstimulation syndrome (OHSS).
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
Menotropins are not indicated during lactation due to lack of data. It is unknown if menotropins are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during therapy. M/P ratio is unknown.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
Menopur is contraindicated during pregnancy. If inadvertent exposure occurs, no dose adjustment is applicable as therapy is discontinued upon pregnancy confirmation. Pharmacokinetic changes in pregnancy (increased plasma volume, altered hormone levels) are not relevant since the drug is not used during gestation.
Do not use in pregnancy. No dose recommendations available; contraindicated.
MENOPUR (menotropins) is a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) used for ovulation induction and controlled ovarian stimulation. Monitor ovarian response with ultrasound and estradiol levels to minimize risk of ovarian hyperstimulation syndrome (OHSS). Adjust dose based on antral follicle count and prior response. For IVF, concomitant gonadotropin-releasing hormone (Gn RH) antagonist or agonist is typically used to prevent premature LH surge. Administer intramuscularly or subcutaneously; reconstitute immediately before use. Multifetal pregnancy rates are high; counsel patients accordingly.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
MENOPUR is a hormone injection used to help your ovaries produce multiple eggs. It is given as a shot under the skin or into a muscle. Your doctor will show you how to prepare and inject the medication. Do not shake the vial after mixing. Use each vial only once and discard any unused medicine.,Common side effects include injection site reactions (pain, redness, swelling), ovarian enlargement, abdominal discomfort, and mood swings. Serious risks include ovarian hyperstimulation syndrome (OHSS) with symptoms like sudden severe abdominal pain, nausea, vomiting, and rapid weight gain. Notify your doctor immediately if you experience these.,You will have frequent blood tests and vaginal ultrasounds to monitor your response. Stick to the schedule and do not change doses without consulting your doctor.,There is a high chance of multiple pregnancy (twins, triplets, etc.). Discuss the risks and implications with your doctor.,Avoid alcohol and smoking during treatment. No specific food restrictions, but maintain a balanced diet to support overall health.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MENOPUR vs ANDEMBRY, answered by our medical review team.
MENOPUR is a Gonadotropin that works by Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MENOPUR and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MENOPUR is: 225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MENOPUR and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MENOPUR is classified as Category C. Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.